On Friday, Climb Bio Inc (NASDAQ: CLYM) was 12.10% up from the session before settling in for the closing price of $1.24. A 52-week range for CLYM has been $1.05 – $9.49.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 41.18%. With a float of $58.19 million, this company’s outstanding shares have now reached $67.58 million.
Considering the fact that the conglomerate employs 18 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Climb Bio Inc (CLYM) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Climb Bio Inc stocks. The insider ownership of Climb Bio Inc is 13.88%, while institutional ownership is 76.29%. The most recent insider transaction that took place on Mar 20 ’25, was worth 1,571. In this transaction SVP, Finance & CAO of this company sold 1,199 shares at a rate of $1.31, taking the stock ownership to the 15,130 shares. Before that another transaction happened on Dec 19 ’24, when Company’s CHIEF ACCOUNTING OFFICER sold 1,235 for $2.02, making the entire transaction worth $2,495. This insider now owns 11,329 shares in total.
Climb Bio Inc (CLYM) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 41.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.24% during the next five years compared to -40.44% drop over the previous five years of trading.
Climb Bio Inc (NASDAQ: CLYM) Trading Performance Indicators
You can see what Climb Bio Inc (CLYM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.37, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Climb Bio Inc (CLYM)
Compared to the last year’s volume of 0.28 million, its volume of 0.29 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 59.73%. Additionally, its Average True Range was 0.10.
During the past 100 days, Climb Bio Inc’s (CLYM) raw stochastic average was set at 33.33%, which indicates a significant decrease from 74.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.48% in the past 14 days, which was higher than the 69.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2406, while its 200-day Moving Average is $2.9412. Nevertheless, the first resistance level for the watch stands at $1.4833 in the near term. At $1.5767, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.6833. If the price goes on to break the first support level at $1.2833, it is likely to go to the next support level at $1.1767. Now, if the price goes above the second support level, the third support stands at $1.0833.
Climb Bio Inc (NASDAQ: CLYM) Key Stats
There are 67,576K outstanding shares of the company, which has a market capitalization of 93.93 million. As of now, sales total 0 K while income totals -73,900 K. Its latest quarter income was 0 K while its last quarter net income were -20,780 K.
